Frontage expands site to accommodate nicotine-related studies, develops assay portfolio

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Rattankun Thongbun)
(Image: Getty/Rattankun Thongbun)

Related tags Frontage Laboratories Clinical trials CRO

Frontage Clinical Services has expanded its site in New Jersey to accommodate nicotine-related studies and is developing a portfolio of assays to evaluate tobacco-specific biomarkers.

Frontage Clinical Services, an associate of the contract research organization (CRO) Frontage Laboratories, has renovated its Secaucus, New Jersey-based site to accommodate tobacco and nicotine-related studies.

“Specialized clinical facilities are needed to control the ventilation in the areas that subjects are allowed to use combustible cigarettes or electronic nicotine delivery systems,” ​explained Gary Steidl, RPh, vice president, Frontage Clinical Services. “Controlling this area allows for blood samples to be collected effectively, even as the subjects continue to use the various devices.”

As part of the expansion, the company has added two dedicated negative-pressure rooms that use displacement ventilation. This enables participants to use various investigational tobacco products, including combustible cigarettes and electronic nicotine delivery systems (ENDS), as well as smoking cessation therapies, according to Frontage.

“These studies are part of addressing an important public health concern related to subjects who use tobacco and other nicotine-containing products.

“It is well known that there are significant health concerns with the use of combustible cigarettes, evaluating new ENDS products or nicotine replacement therapies can help provide alternatives to those who continue to use cigarettes,”​ Steidl told us.

In addition to the site expansion, Frontage Labs’ bioanalytical lab is developing an assay portfolio to evaluate tobacco-specific biomarkers of exposure and potential harm.

Additionally, the company last year acquired Concord Biosciences​, a preclinical CRO located on a 20-acre campus near Cleveland, OH. The company conducts drug safety, metabolism, bioanalytical, residue and environmental fate studies.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more